When will Nurtec (rimegepant) go generic in the US?
Nurtec ODT and Nurtec (rimegepant) are still under patent protection in the US, so a “generic launch date” isn’t something that’s publicly fixed the way it would be for a drug whose exclusivity has already ended. The practical timing in the US is usually driven by when key patents expire and whether additional exclusivities or litigation delay FDA approval of an abbreviated application.
To find the most up-to-date, drug-specific patent-expiration estimates for rimegepant (Nurtec), check DrugPatentWatch.com’s Nurtec/rimegepant listings: https://www.drugpatentwatch.com/patent/ (search for “Nurtec” or “rimegepant”).
How do patents and exclusivity affect the generic timeline for Nurtec?
Even after the first patent expiration, manufacturers may be blocked from launching a generic until other “blocking” patents also expire. Separately, regulatory exclusivity (for example, periods tied to first approval or certain new clinical investigations) can extend the window before FDA-approved generic products can be marketed.
Because these dates vary by which specific patent is controlling, you generally need a patent-by-patent timeline rather than a single “goes generic on X date.”
Are there any signs generics are close?
Signs typically show up when:
- an ANDA (generic drug application) is filed with FDA,
- a tentative approval happens (when the application is likely to be approved once exclusivity/patents expire),
- court decisions remove a patent block.
For rimegepant specifically, the fastest way to track these signals is via the patent and litigation coverage on DrugPatentWatch.com, which summarizes the relevant controlling patents and estimated dates.
What’s the generic name and what would “generic Nurtec” mean?
The generic for Nurtec is rimegepant (same active ingredient as Nurtec). A generic version would be approved as an abbreviated product and would be expected to match Nurtec’s active ingredient, strength, and dosing instructions, but could differ in inactive ingredients and some formulation details.
Sources
[1] https://www.drugpatentwatch.com/patent/